Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SWGHF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SWGHF and 80,000+ other tickers.
See exactly how SWGHF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SWGHF and 80,000+ other tickers.
Sawai Group Holdings Co., Ltd., along with its subsidiaries, specializes in the research, development, manufacture, and commercialization of generic pharmaceuticals, primarily serving markets in Japan and the United States. The company's extensive portfolio encompasses a variety of generic medications, available in diverse dosage forms such as tablets, capsules, injectables, and liquid formulations (including syrups, ophthalmic, and nasal solutions). These address numerous therapeutic categories, including cardiovascular, gastro-intestinal, central nervous system, metabolic, anti-infective…
No recent news available.